MovDisordV3, PubMed, Checkpoint, bibRecord, 002D07

Glutamate release inhibition ineffective in levodopa-induced motor complications.

Identifieur interne : 002D07 ( PubMed/Checkpoint ); précédent : 002D06; suivant : 002D08

Glutamate release inhibition ineffective in levodopa-induced motor complications.

Auteurs : William Bara-Jimenez [États-Unis] ; Tzvetelina D. Dimitrova ; Abdullah Sherzai ; Murat Aksu ; Thomas N. Chase

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.

RBID : pubmed:16758479

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Dyskinesia, Drug-Induced (drug therapy), Excitatory Amino Acid Antagonists (therapeutic use), Female, Glutamic Acid (metabolism), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Riluzole (adverse effects), Riluzole (therapeutic use), Treatment Outcome.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa, Riluzole.
- chemical , metabolism : Glutamic Acid.
- chemical , therapeutic use : Antiparkinson Agents, Excitatory Amino Acid Antagonists, Levodopa, Riluzole.
- drug effects : Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Treatment Outcome.

Abstract

Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD.

DOI: 10.1002/mds.20976
PubMed: 16758479

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002C11
to stream PubMed, to step Curation: 002C11

Links to Exploration step

pubmed:16758479

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glutamate release inhibition ineffective in levodopa-induced motor complications.</title>
<author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
<affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. baraw@ninds.nih.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dimitrova, Tzvetelina D" sort="Dimitrova, Tzvetelina D" uniqKey="Dimitrova T" first="Tzvetelina D" last="Dimitrova">Tzvetelina D. Dimitrova</name>
</author>
<author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
</author>
<author><name sortKey="Aksu, Murat" sort="Aksu, Murat" uniqKey="Aksu M" first="Murat" last="Aksu">Murat Aksu</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N" last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.20976</idno>
<idno type="RBID">pubmed:16758479</idno>
<idno type="pmid">16758479</idno>
<idno type="wicri:Area/PubMed/Corpus">002C11</idno>
<idno type="wicri:Area/PubMed/Curation">002C11</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D07</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Glutamate release inhibition ineffective in levodopa-induced motor complications.</title>
<author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
<affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. baraw@ninds.nih.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dimitrova, Tzvetelina D" sort="Dimitrova, Tzvetelina D" uniqKey="Dimitrova T" first="Tzvetelina D" last="Dimitrova">Tzvetelina D. Dimitrova</name>
</author>
<author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
</author>
<author><name sortKey="Aksu, Murat" sort="Aksu, Murat" uniqKey="Aksu M" first="Murat" last="Aksu">Murat Aksu</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N" last="Chase">Thomas N. Chase</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Female</term>
<term>Glutamic Acid (metabolism)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Riluzole (adverse effects)</term>
<term>Riluzole (therapeutic use)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Glutamic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16758479</PMID>
<DateCreated><Year>2006</Year>
<Month>09</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>02</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>08</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>21</Volume>
<Issue>9</Issue>
<PubDate><Year>2006</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Glutamate release inhibition ineffective in levodopa-induced motor complications.</ArticleTitle>
<Pagination><MedlinePgn>1380-3</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD.</AbstractText>
<CopyrightInformation>(c) 2006 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bara-Jimenez</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. baraw@ninds.nih.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dimitrova</LastName>
<ForeName>Tzvetelina D</ForeName>
<Initials>TD</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sherzai</LastName>
<ForeName>Abdullah</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Aksu</LastName>
<ForeName>Murat</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chase</LastName>
<ForeName>Thomas N</ForeName>
<Initials>TN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3KX376GY7L</RegistryNumber>
<NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber>
<NameOfSubstance UI="D019782">Riluzole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018691">Excitatory Amino Acid Antagonists</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018698">Glutamic Acid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019782">Riluzole</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20976</ArticleId>
<ArticleId IdType="pubmed">16758479</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Aksu, Murat" sort="Aksu, Murat" uniqKey="Aksu M" first="Murat" last="Aksu">Murat Aksu</name>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N" last="Chase">Thomas N. Chase</name>
<name sortKey="Dimitrova, Tzvetelina D" sort="Dimitrova, Tzvetelina D" uniqKey="Dimitrova T" first="Tzvetelina D" last="Dimitrova">Tzvetelina D. Dimitrova</name>
<name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D07 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002D07 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:16758479
   |texte=   Glutamate release inhibition ineffective in levodopa-induced motor complications.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:16758479" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Glutamate release inhibition ineffective in levodopa-induced motor complications.

Glutamate release inhibition ineffective in levodopa-induced motor complications.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki